| Topic | DCM2A-specific summary | General DCM context / extrapolation | Suggested ontology terms / identifiers | Key citations |
|---|---|---|---|---|
| Definition / scope | Dilated cardiomyopathy 2A (DCM2A; historically CMD2A) is a rare **autosomal recessive** cardiomyopathy caused by **biallelic TNNI3 loss-of-function** variants, usually presenting as severe neonatal/infantile dilated cardiomyopathy; broader heterozygous TNNI3-associated cardiomyopathies are a different entity. | Broader DCM is genetically heterogeneous and includes monogenic, oligogenic, and acquired forms. | **OMIM:** 611880; suggested disease terms: dilated cardiomyopathy, infantile-onset cardiomyopathy | (pqac-00000004, pqac-00000007) |
| Causal gene and inheritance | **TNNI3** (cardiac troponin I) is the established causal gene for DCM2A when variants are **biallelic** and loss-of-function; inheritance is **autosomal recessive**. Consanguinity is reported in some families but is not required. | In general DCM, pathogenic variants are found in many genes; pediatric cases often have higher genetic diagnostic yield than adult cases. | **Gene:** TNNI3; suggested HGNC symbol: TNNI3; inheritance: AR | (pqac-00000002, pqac-00000004, pqac-00000009) |
| Hallmark phenotype / onset | Hallmark presentation is **early severe systolic dysfunction with LV dilation**, often in the first months of life, with low LVEF, heart failure symptoms (dyspnea, feeding difficulty), and occasional LV noncompaction overlap. Disease course is usually rapidly progressive. | General pediatric DCM can present across childhood, but infancy is a particularly vulnerable period. | **HPO:** Dilated cardiomyopathy HP:0001644; Left ventricular systolic dysfunction HP:0005162; Heart failure HP:0001635; Dyspnea HP:0002094; Feeding difficulties HP:0011968; Left ventricular noncompaction HP:0006677 | (pqac-00000000, pqac-00000001, pqac-00000002) |
| Strongest disease-specific statistics | In the 2023 disease-focused review/case series, **20 documented biallelic TNNI3 cases** were summarized, of which **16/20 had DCM phenotype**; onset was consistently early and outcomes were typically severe, often requiring transplant soon after diagnosis. | By contrast, general genetic DCM is much more common and genetically diverse; up to ~40% of idiopathic/familial DCM has an identifiable genetic basis. | Evidence type: human case reports / case series | (pqac-00000000, pqac-00000007, pqac-00000009) |
| Recurrent variants and frequencies | Recurrent DCM2A-associated variants include **p.Arg69Alafs\*8** and **p.Arg98\***. Reported carrier frequencies in population data summarized in the 2023 review were approximately **1/26,222** for p.Arg69Alafs\*8 and **1/17,750** for p.Arg98\*; healthy heterozygous carrier frequency overall was summarized as **48/100,000**. In two 2023 patients, homozygous **c.292C>T (p.Arg98\*)** caused severe infantile DCM. | Heterozygous TNNI3 variants more commonly relate to hypertrophic/restrictive cardiomyopathy and do not define DCM2A. | Variant classes: nonsense, frameshift, splice-altering / null | (pqac-00000000, pqac-00000001, pqac-00000003) |
| Mechanism / pathophysiology | Core mechanism is **loss of cTnI function** due to biallelic TNNI3 null variants, often through **nonsense-mediated decay** with markedly reduced or absent TNNI3 mRNA/protein in myocardium; compensatory upregulation of fetal **TNNI1** has been reported. Expected downstream effect is impaired sarcomeric thin-filament inhibition and abnormal excitation-contraction coupling leading to contractile failure, ventricular dilation, and heart failure. | General DCM literature supports sarcomeric dysfunction, calcium-handling abnormalities, remodeling, fibrosis, and arrhythmia susceptibility as common downstream pathways. | **GO:** sarcomere organization GO:0045214; cardiac muscle contraction GO:0060048; regulation of cardiac muscle contraction by calcium ion signaling GO:0010882; **CL:** cardiomyocyte CL:0002494; **UBERON:** heart UBERON:0000948, left ventricle UBERON:0002084 | (pqac-00000002, pqac-00000000, pqac-00000007) |
| Diagnosis | Most disease-specific diagnoses have been made by **echocardiography plus molecular testing**. Practical approach: infant/pediatric cardiomyopathy work-up with ECG, echocardiography, family history, and **multigene panel / WES**, interpreted with genetic counseling; test the most clearly affected proband first, then cascade test relatives if a familial variant is found. | This diagnostic strategy is extrapolated from pediatric/genetic DCM practice, where genetic testing is recommended and informative for prognosis and family screening. | Suggested tests: echocardiography, ECG, cardiac MRI when feasible, multigene cardiomyopathy panel, WES/WGS as needed | (pqac-00000001, pqac-00000011, pqac-00000009) |
| Treatment / prognosis | No approved **TNNI3-specific** therapy was identified. Reported DCM2A patients were managed with advanced heart-failure care; severe infant cases often required **ECMO/VAD bridge** and **heart transplantation**, with favorable post-transplant short-term outcomes in the two 2023 cases. Overall prognosis appears poor without advanced support because progression is often rapid. | Extrapolated standard DCM/HFrEF care includes beta-blocker, ARNI/ACEi/ARB, MRA, and SGLT2 inhibitor when age/clinical status allow; refractory pediatric cases may need mechanical support/transplant. | **NCIT suggestions:** Heart Transplantation, Ventricular Assist Device, Extracorporeal Membrane Oxygenation, Genetic Counseling | (pqac-00000001, pqac-00000005, pqac-00000006) |
| Prevention / risk modification | No primary prevention exists for genetically affected homozygotes beyond reproductive counseling and at-risk family identification. Secondary prevention is **cascade screening** of relatives and early cardiac surveillance in genetically at-risk family members. | General DCM counseling includes avoiding cardiotoxic exposures and recognizing that pregnancy, alcohol, chemotherapy, and other triggers can worsen some genetic DCMs, though this has not been shown specifically for DCM2A. | Suggested counseling terms: cascade screening, reproductive counseling, family screening | (pqac-00000011, pqac-00000006, pqac-00000010) |
| Major evidence gaps | Very small number of published patients; phenotype frequencies remain imprecise; penetrance estimates for heterozygous relatives are uncertain; no confidently retrieved MONDO/Orphanet ID; no disease-specific biomarker, natural-history registry, or approved targeted therapy identified; no well-validated DCM2A-specific animal model was retrieved, and **TNNI3K** studies must not be confused with **TNNI3** disease biology. | General DCM research is rapidly evolving, but its findings cannot be assumed to apply directly to recessive TNNI3-null infantile disease. | Curation note: do **not** infer TNNI3K knockout data as DCM2A evidence | (pqac-00000013, pqac-00000000, pqac-00000011) |


*Table: This table compacts the highest-yield knowledge-base facts for Dilated Cardiomyopathy 2A, separating subtype-specific evidence from broader dilated cardiomyopathy context. It is useful for rapid curation of identifiers, phenotype, mechanism, diagnosis, and current evidence gaps.*